Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-18T13:00:27.154Z Has data issue: false hasContentIssue false
  • English
  • Français

The Role of Long Acting Antipsychotics in Bipolar Disorder

Published online by Cambridge University Press:  23 March 2020

E. Vieta
E. Vieta*
Affiliation:
Hospital Clinic de Barcelona, Psychiatry Bipolar Disorders Program, Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Antipsychotics are widely used for the short and long-term treatment of bipolar disorder. Depot and long-acting injectable formulations (LAIs) can be particularly useful for certain subgroups of patients. This lecture will discuss the available data from randomized controlled trials of LAIs in bipolar disorder. A recently published meta-analysis and individual studies assessing depot medications, as well as modern LAIs such as risperidone, paliperidone and aripiprazole, will be reviewed, looking carefully into the prevention of either pole of illness and tolerability. Potential indications and patient profile, based on data and clinical experience, will be discussed.

Disclosure of interest

The author has not supplied his declaration of competing interest.

Type
Symposium: New avenues in the management of bipolar disorder
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S15
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.